South Korea reports blood clots after AstraZeneca vaccine

South Korea reports blood clots after AstraZeneca vaccine
Symptoms curable if detected early and treated properly, says disease agency chief

Medics in 韩国 have reported the country’s first case of rare blood clotting linked to the 阿斯利康 新冠病毒 疫苗.

A medical facility worker in his 30s was taken to hospital on 12 May after receiving the jab on 27 四月. He developed a headache on 9 May before falling seriously ill, and also suffered muscle cramps.

Jeong Eun-kyeong, director of the Korea Disease Control and Prevention Agency (KDCA), said in a statement: “His condition has improved since then and we understand there is no big problem though he still needs monitoring.”

The symptoms of blood clotting are curable if detected early and treated properly, she added.

About 3.27 million people in South Korea have been given at least one dose of the AstraZeneca vaccine so far. Seoul limited its use to the over-30s following the initial reports of blood clotting elsewhere in the world.

Those reports have mainly concerned a type of blood clot called cerebral venous sinus thrombosis. The condition has been seen in combination with low blood platelet levels, called thrombocytopenia.

Medical regulators in the US and Europe have concluded that there appears to be a link between AstraZeneca’s vaccine, as well as one made by Johnson & 约翰逊, and the clots, but they say the shots are safe and that the benefits of being vaccinated outweigh the risks.

AstraZeneca has said it is working to understand individual cases and “possible mechanisms that could explain these extremely rare events”, while J&J has said that no clear causal relationship has been established between the vaccine and the clots.

The KDCA reported 430 new coronavirus cases as of Sunday, for a total of 140,340 cases with 1,959 死亡人数.

Additional reporting by Reuters


您的电子邮件地址不会被公开. 必需的地方已做标记 *